Onconetix (ONCO) Q2 2026 earnings summary

Executive summary

• Focused on commercializing Proclarix, a prostate cancer diagnostic, after abandoning ENTADFI due to resource constraints and impaired assets.

• Revenue declined significantly year-over-year due to lower product sales and reduced demand.

• Two reverse stock splits were executed in March and May 2026 to maintain Nasdaq compliance.

• Entered into a Share Exchange Agreement to acquire Realbotix, subject to closing conditions and significant funding requirements.

Financial highlights

• Revenue for the three and six months ended June 30, 2026, was $17,120 and $38,577, down 83.9% and 81.5% year-over-year, respectively.

• Net loss for the three and six months ended June 30, 2026, was $2.87 million and $7.08 million, respectively, compared to $2.37 million and $10.92 million in the prior year.

• Gross margin dropped to 25.1% for the quarter and 6.9% for the half-year, reflecting fixed costs amid lower sales.

• Operating expenses increased 36.4% for the quarter and 34.0% for the half-year, mainly due to higher professional fees and impairment charges.

• Accumulated deficit reached $138.3 million as of June 30, 2026.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for the foreseeable future.

• Additional capital is required to fund operations, commercialize Proclarix, and close the Realbotix transaction.

• Recent Series F PIPE financing and new ELOC provide some liquidity but are insufficient for long-term needs.